Dr. Mammen’s mission is to work with the best research and development professionals in the world to make meaningful medicines that impact the lives of patients, their families and communities.

Till recently Mathai was Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson (J&J), Mathai's mission is to focus the energy of the best research and development teams in the world at the intersection of unmet medical need and breakthroughs in science and technology to make medicines with unequivocal benefit for patients worldwide. His team works across a wide range of therapeutic areas and biological pathways to deliver that impact, including: Oncology, Cardiovascular, Metabolic and Retinal Disease, Pulmonary Hypertension, Immunology, Neuroscience, and Infectious Disease and Vaccines.

Mathai is redefining how drugs are discovered and developed, investing deeply in Data Science throughout every aspect of R&D and in immunology across all disease areas. He is also strongly committed to improving access to make medicines and vaccines for all parts of the globe.

After joining Janssen in June 2017, Mathai built on an already strong foundation to create a truly world-class portfolio, and under his leadership, the organization has advanced seven new FDA-approved prescription medicines and 30 additional approvals for expanded indications or new product formulations to benefit hundreds of millions of patients. Agnostic to the source of innovation, Janssen R&D has also executed more than 40 acquisitions and licenses, and more than 350 strategic partnerships and collaborations to advance its industry-leading portfolios.

Mathai is an inclusive leader, passionate about talent development, and a champion of diversity. He is the executive sponsor of J&J’s Data Science Council, and his patient-first approach has helped fuel Janssen to be one of the largest pharmaceutical companies in the world.

Prior to joining Janssen, Mathai held senior leadership positions at Merck Research Laboratories. He previously led R&D at Theravance, a company he co-founded in the San Francisco Bay Area, which created 31 development candidates and five approved products. Mathai and the team later created Innoviva, a second successful publicly traded company focused on royalty management.

Mathai has more than 150 peer-reviewed publications and patents, and serves on various boards and advisory committees, including 10x Genomics, MIT Abdul Latif Jameel Clinic for Machine Learning in Health, Institute for Medical Engineering and Science and MIT, President’s Advisory Committee for Dalhousie University, and the Vagelos Life Science Management Program at the University of Pennsylvania. He received his M.D. from Harvard Medical School/Massachusetts Institute of Technology (HST program) and his Ph.D. in Chemistry from Harvard University Department of Chemistry, working with George Whitesides. He received his BSc in Chemistry and Biochemistry from Dalhousie University in Halifax, Nova Scotia.